
UK becomes first to authorize Merck and Ridgeback Biotherapeutics' antiviral molnupiravir to treat mild-to-moderate Covid-19
CNN
The UK Medicines and Healthcare Products Regulatory Agency said Thursday it had authorized Merck and Ridgeback Biotherapeutics' oral antiviral, molnupiravir, to treat mild-to-moderate Covid-19 in adults at risk for severe illness.
It is the world's first oral antiviral to be authorized anywhere for the treatment of Covid-19. The drug comes in capsule form and will be known as Lagevrio.
The companies have sought US Food and Drug Administration emergency use authorization for the drug, and the FDA said it will convene its Antimicrobial Drugs Advisory Committee on November 30 to discuss molnupiravir's ability to treat mild-to-moderate Covid-19 in adults who are at high risk for severe disease, including hospitalization or death.

Former Navy sailor sentenced to 16 years for selling information about ships to Chinese intelligence
A former US Navy sailor convicted of selling technical and operating manuals for ships and operating systems to an intelligence officer working for China was sentenced Monday to more than 16 years in prison, prosecutors said.

The Defense Department has spent more than a year testing a device purchased in an undercover operation that some investigators think could be the cause of a series of mysterious ailments impacting spies, diplomats and troops that are colloquially known as Havana Syndrome, according to four sources briefed on the matter.











